Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide 2.4 mg vs. other anti-obesity medications in obesity
NCT05579249Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2023
- Primary completion
- Nov 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of semaglutide in obesity (2 arms), sponsored by Novo Nordisk. Primary endpoint: Number of Participants Who Achieved Greater Than or Equal to 10.0 Percent Body Weight Reduction at 52 weeks. Started Jan 2023; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05579249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05579249.